Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-Essential Thrombocytosis Myelofibrosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Lucia Masarova, MD)
Study leads
Lucia Masarova, MD
Principal Investigator
M.D. Anderson Cancer Center